《大行報告》匯豐研究上調新秀麗(01910.HK)目標價至34元 評級「買入」
匯豐研究發表研究報告指出,基於內地在疫情後重新開放,預期今年新秀麗(01910.HK)亞洲按年增長超過60%,顯著跑贏其他地區,而今年初亞洲區銷售錄得爆炸性增長,首季銷售按年增長80%,較2019年疫情前增長10%。而在該行覆蓋的消費股中,新秀麗是其中一隻表現最好的股份。
該行將新秀麗的今明兩年盈利預測各上調14%及10%,目標價由30元上調至34元,維持「買入」評級,認為現時對該股部署還為時未晚。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.